

Step Therapy Criteria for Drugs on the 2022 Global Classic (HMO), Global Special Care (HMO C-SNP), and Global Special Care Savings (HMO C-SNP) Formularies

The following are step therapy criteria for drugs on the 2022 Global Classic (HMO), Global Special Care (HMO C-SNP), and Global Special Care Savings (HMO C-SNP) formularies. To determine if your drug has a step therapy requirement, use the GlobalHealth online prescription search specific to your plan at <u>www.GlobalHealth.com</u>. To request an exception (also called a coverage determination) to the step therapy criteria for any of these drugs <u>click here</u>.

This step therapy criteria document is current as of 10/15/2021. For more recent information or other questions, please contact Customer Care at 1-844-449-0360 (TTY 711), 24 hours a day, 7 days a week.

Step Therapy Criteria

Step Therapy Group	PPI
Drug Names	ESOMEPRAZOLE MAGNESIUM
Step Therapy Criteria	Coverage will be provided if two of the following generic alternatives: omeprazole capsules, pantoprazole tablets, or lansoprazole capsules have been tried (at least a 30 day supply in the prior 180 days).
Step Therapy Group	URINARY ANTISPASMODICS
Drug Names	TOLTERODINE TARTRATE, TOLTERODINE TARTRATE ER
Step Therapy Criteria	Coverage will be provided if fesoterodine, mirabegron, oxybutynin, oxybutynin extended-release, solifenacin tablets, or trospium immediate-release has been tried (at least a 30-day supply in the prior 180 days).